NetworkNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Advances AI-Driven Oncology Pipeline, Establishes Open Medicine AI
Lantern Pharma (NASDAQ: LTRN), reported second-quarter 2026 operational and financial results, highlighting progress across its AI-driven oncology pipeline and the establishment of Open Medicine AI (“OMAI”) as a separate company. Emerging data from the Phase 2 HARMONIC(TM) trial showed LP-300’s progression-free survival benefit deepening with treatment duration in patients with EGFR exon 21 L858R mutations, while the FDA reviewed key protocol amendments without objection. The European Medicines Agency cleared an investigator-initiated Phase 1b/2 trial of LP-184, or zirdafulven, in biomarker-selected advanced bladder cancer, while the U.S. Patent and Trademark Office issued a Notice of Allowance covering a three-gene patient-selection signature…







